Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Gastroenterology
Published in: Current Treatment Options in Gastroenterology 4/2018

01-12-2018 | Invited Commentary

Opioid-Induced Esophageal Dysfunction: An Emerging Entity with Sweeping Consequences

Authors: Dhyanesh Patel, MD, Michael Vaezi, MD, PhD

Published in: Current Treatment Options in Gastroenterology | Issue 4/2018

Login to get access

Abstract

Adverse effects of opioids on the gastrointestinal tract are well known. However, with the rising epidemic of opioids, its detrimental effects on esophageal physiology are now being increasingly recognized. In this commentary, we briefly review the current evidence behind opioid-induced esophageal dysfunction with potential pathophysiology and treatment options.
Literature
1.
Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156:569–76.CrossRef
2.
Choung RS, Locke GR 3rd, Zinsmeister AR, et al. Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study. Am J Gastroenterol. 2009;104:1199–204.CrossRef
3.
Gomes T, Tadrous M, Mamdani MM, et al. The burden of opioid-related mortality in the United States. JAMA Network Open. 2018;1:e180217.CrossRef
4.
Camilleri M, Lembo A, Katzka DA. Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits. Clin Gastroenterol Hepatol. 2017;15:1338–49.CrossRef
5.
Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106:835–42.CrossRef
6.
Dowlatshahi K, Evander A, Walther B, et al. Influence of morphine on the distal oesophagus and the lower oesophageal sphincter--a manometric study. Gut. 1985;26:802–6.CrossRef
7.
Penagini R, Bianchi PA. Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology. 1997;113:409–14.CrossRef
8.
Kraichely RE, Arora AS, Murray JA. Opiate-induced oesophageal dysmotility. Aliment Pharmacol Ther. 2010;31:601–6.CrossRef
9.
Penagini R, Picone A, Bianchi PA. Effect of morphine and naloxone on motor response of the human esophagus to swallowing and distension. Am J Physiol. 1996;271:G675–80.PubMed
10.
Gonzalez ES, Bellver VO, Jaime FC, et al. Opioid-induced lower esophageal sphincter dysfunction. J Neurogastroenterol Motil. 2015;21:618–20.CrossRef
11.
Ratuapli SK, Crowell MD, DiBaise JK, et al. Opioid-induced esophageal dysfunction (OIED) in patients on chronic opioids. Am J Gastroenterol. 2015;110:979–84.CrossRef
12.
Savilampi J, Magnuson A, Ahlstrand R. Effects of remifentanil on esophageal motility: a double-blind, randomized, cross-over study in healthy volunteers. Acta Anaesthesiol Scand. 2015;59:1126–36.CrossRef
13.
Ravi K, Murray JA, Geno DM, et al. Achalasia and chronic opiate use: innocent bystanders or associated conditions? Dis Esophagus. 2016;29:15–21.CrossRef
14.
Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16(Suppl 2):17–28.CrossRef
15.
Sternini C, Patierno S, Selmer IS, et al. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004;16(Suppl 2):3–16.CrossRef
16.
Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol. 1993;16:1–18.CrossRef
17.
Greenwald MK, Stitzer ML, Haberny KA. Human pharmacology of the opioid neuropeptide dynorphin A(1–13). J Pharmacol Exp Ther. 1997;281:1154–63.PubMed
18.
Bagnol D, Mansour A, Akil H, et al. Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience. 1997;81:579–91.CrossRef
19.
Rattan S, Goyal RK. Identification and localization of opioid receptors in the opossum lower esophageal sphincter. J Pharmacol Exp Ther. 1983;224:391–7.PubMed
20.
Scarpellini E, Pauwels A, Vos R, et al. Effect of methylnaltrexone and naloxone on esophageal motor function in man. Neurogastroenterol Motil. 2017;29.CrossRef
21.
Kahrilas PJ, Bredenoord AJ, Carlson DA, et al. Advances in management of esophageal motility disorders. Clin Gastroenterol Hepatol 2018.
22.
Ortiz V, Garcia-Campos M, Saez-Gonzalez E, et al. A concise review of opioid-induced esophageal dysfunction: is this a new clinical entity?. Dis Esophagus 2018;31.
Metadata
Title
Opioid-Induced Esophageal Dysfunction: An Emerging Entity with Sweeping Consequences
Authors
Dhyanesh Patel, MD
Michael Vaezi, MD, PhD
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Treatment Options in Gastroenterology / Issue 4/2018
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-018-0210-2

Other articles of this Issue 4/2018

Current Treatment Options in Gastroenterology 4/2018 Go to the issue

Invited Commentary

Timing of Endoscopic Necrosectomy Following Transmural Stent Placement for Pancreatic Necrosis

Motility (H Parkman and R Schey, Section Editors)

Parkinson’s Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects

Stomach (P Malfertheiner, Section Editor)

Gastroduodenal “Dysbiosis”: a New Clinical Entity

Pancreas (V Chandrasekhara, Section Editor)

Endoscopic Ultrasound-Guided Management of Pain in Chronic Pancreatitis and Pancreatic Cancer: an Update

Pancreas (V Chandrasekhara, Section Editor)

Pancreatic Cancer and Diabetes Mellitus

Pancreas (V Chandrasekhara, Section Editor)

Recurrent Acute Pancreatitis: Current Concepts in the Diagnosis and Management
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits